AEZS
Price
$1.95
Change
-$0.00 (-0.00%)
Updated
Apr 19, 6:59 PM EST
17 days until earnings call
CUE
Price
$1.56
Change
-$0.02 (-1.27%)
Updated
Apr 19, 6:59 PM EST
17 days until earnings call
Ad is loading...

Compare trend and price AEZS vs CUE

Header iconAEZS vs CUE Comparison
Open Charts AEZS vs CUEBanner chart's image
Aeterna Zentaris
Price$1.95
Change-$0.00 (-0.00%)
Volume$4.48K
CapitalizationN/A
Cue Biopharma
Price$1.56
Change-$0.02 (-1.27%)
Volume$119.94K
CapitalizationN/A
View a ticker or compare two or three
AEZS vs CUE Comparison Chart

Loading...

AEZSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CUEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AEZS vs. CUE commentary
Apr 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AEZS is a StrongSell and CUE is a Sell.

COMPARISON
Comparison
Apr 20, 2024
Stock price -- (AEZS: $1.95 vs. CUE: $1.56)
Brand notoriety: AEZS and CUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AEZS: 27% vs. CUE: 61%
Market capitalization -- AEZS: $9.41M vs. CUE: $76.37M
AEZS [@Biotechnology] is valued at $9.41M. CUE’s [@Biotechnology] market capitalization is $76.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $550.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AEZS’s FA Score shows that 0 FA rating(s) are green whileCUE’s FA Score has 0 green FA rating(s).

  • AEZS’s FA Score: 0 green, 5 red.
  • CUE’s FA Score: 0 green, 5 red.
According to our system of comparison, CUE is a better buy in the long-term than AEZS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AEZS’s TA Score shows that 3 TA indicator(s) are bullish while CUE’s TA Score has 4 bullish TA indicator(s).

  • AEZS’s TA Score: 3 bullish, 6 bearish.
  • CUE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CUE is a better buy in the short-term than AEZS.

Price Growth

AEZS (@Biotechnology) experienced а -1.27% price change this week, while CUE (@Biotechnology) price change was -10.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.06%. For the same industry, the average monthly price growth was -5.49%, and the average quarterly price growth was +1224.51%.

Reported Earning Dates

AEZS is expected to report earnings on Aug 08, 2024.

CUE is expected to report earnings on Sep 02, 2024.

Industries' Descriptions

@Biotechnology (-7.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AEZS with price predictions.
OPEN
A.I.dvisor published
a Summary for CUE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CUE($76.4M) has a higher market cap than AEZS($9.41M). AEZS YTD gains are higher at: 5.194 vs. CUE (-40.909).
AEZSCUEAEZS / CUE
Capitalization9.41M76.4M12%
EBITDAN/AN/A-
Gain YTD5.194-40.909-13%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
AEZS vs CUE: Fundamental Ratings
AEZS
CUE
OUTLOOK RATING
1..100
6156
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
5789
P/E GROWTH RATING
1..100
92100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CUE's Valuation (35) in the Biotechnology industry is in the same range as AEZS (54). This means that CUE’s stock grew similarly to AEZS’s over the last 12 months.

CUE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AEZS (100). This means that CUE’s stock grew similarly to AEZS’s over the last 12 months.

AEZS's SMR Rating (97) in the Biotechnology industry is in the same range as CUE (98). This means that AEZS’s stock grew similarly to CUE’s over the last 12 months.

AEZS's Price Growth Rating (57) in the Biotechnology industry is in the same range as CUE (89). This means that AEZS’s stock grew similarly to CUE’s over the last 12 months.

AEZS's P/E Growth Rating (92) in the Biotechnology industry is in the same range as CUE (100). This means that AEZS’s stock grew similarly to CUE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AEZSCUE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 23 days ago
74%
Bullish Trend 19 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
AEZSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CUEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GAIA3.930.14
+3.69%
Gaia
STC60.521.32
+2.23%
Stewart Information Services Corp
ARZGY12.050.09
+0.75%
Assicurazioni Generali Spa Ord
ADTN4.69-0.04
-0.85%
ADTRAN Holdings
BILL59.61-1.38
-2.26%
BILL Holdings

AEZS and

Correlation & Price change

A.I.dvisor tells us that AEZS and JANX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AEZS and JANX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AEZS
1D Price
Change %
AEZS100%
-1.18%
JANX - AEZS
29%
Poorly correlated
+1.86%
SLDB - AEZS
29%
Poorly correlated
-7.31%
FATE - AEZS
27%
Poorly correlated
-4.36%
CALC - AEZS
26%
Poorly correlated
-7.60%
APRE - AEZS
25%
Poorly correlated
-2.09%
More